Physician profile
Edward E Graul
NPI 1447228945
$2,071.72
in general payments reported to CMS, 2019-2025
21 companies · $35.08 in 2025
The $35.08 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $511 · 2020: $186 · 2021: $344 · 2022: $276 · 2023: $473 · 2024: $246 · 2025: $35.08.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $755.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $754.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $358.14 | 2019-2024 | Clareon, Rocklatan, Wavelight Ex500 Excimer Laser |
| Novartis Pharmaceuticals Corporation | $343.61 | 2019-2022 | |
| Allergan, INC. | $220.50 | 2019-2022 | |
| Abbvie INC. | $140.09 | 2023-2025 | |
| Johnson & Johnson Surgical Vision, INC. | $110.84 | 2023 | Tecnis Iol, Catalys System, Tecnis Simplicity |
| Sun Pharmaceutical Industries INC. | $108.54 | 2019-2024 | Cequa |
| Mallinckrodt Hospital Products INC. | $106.08 | 2021-2023 | Acthar |
| Bausch & Lomb Americas INC. | $102.08 | 2023-2024 | Xiidra, Envista Mx60 Iol, Victus |
| Oyster Point Pharma, INC. | $86.70 | 2023 | Tyrvaya |
| Aerie Pharmaceuticals, INC. | $84.80 | 2019-2021 | |
| Biotissue Holdings INC. | $64.06 | 2021-2024 | |
| Carl Zeiss Meditec USA, INC. | $60.85 | 2021 | |
| Lkc Technologies, INC. | $56.44 | 2023 | |
| Ivantis, INC | $52.90 | 2020-2021 | |
| Optos, INC. | $46.04 | 2019 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eyevance Pharmaceuticals LLC | $30.10 | 2021-2022 | |
| Kala Pharmaceuticals, INC. | $24.98 | 2021 | |
| Tarsus Pharmaceuticals, INC. | $24.78 | 2024 | Xdemvy |
| Harrow Eye, LLC | $19.54 | 2024 | Vevye |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $16.07 | 2020 | |
| Glaukos Corporation | $14.58 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edward Graul listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.